請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/29190
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 高純琇 | |
dc.contributor.author | Zong-Jhen Li | en |
dc.contributor.author | 李宗蓁 | zh_TW |
dc.date.accessioned | 2021-06-13T01:02:38Z | - |
dc.date.available | 2010-08-08 | |
dc.date.copyright | 2007-08-08 | |
dc.date.issued | 2007 | |
dc.date.submitted | 2007-07-25 | |
dc.identifier.citation | 1. Lee YC, Yang MC, Huang YT, Liu CH, Chen SB. Impacts of cost containment strategies on pharmaceutical expenditures of the National Health Insurance in Taiwan, 1996-2003. Pharmacoeconomics 2006;24(9):891-902.
2. 程馨.謝啟瑞. 全民健保藥品政策與藥品費用的經濟分析. 經社法制論叢 2005;35:1-42. 3. Narrow WE, Rae DS, Robins LN, Regier DA. Revised prevalence estimates of mental disorders in the United States: using a clinical significance criterion to reconcile 2 surveys' estimates. Arch Gen Psychiatry 2002 Feb;59(2):115-123. 4. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003 Jun 18;289(23):3095-3105. 5. Anonymous. Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. Am J Psychiatry 2000 Apr;157(4 Suppl):1-45. 6. Bauer M, Whybrow PC, Angst J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder.[see comment]. World J Biol Psychiatry 2002 Jan;3(1):5-43. 7. Ellis P. Australian and New Zealand clinical practice guidelines for the treatment of depression. Aust N Z J Psychiatry 2004 Jun;38(6):389-407. 8. Geddes JR, Freemantle N, Mason J, Eccles MP, Boynton J. SSRIs versus other antidepressants for depressive disorder. Cochrane Database Syst Rev 2000(2):CD001851. 9. Song F, Freemantle N, Sheldon TA, et al. Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. Bmj 1993 Mar 13;306(6879):683-687. 10. Williams JW, Jr., Mulrow CD, Chiquette E, Noel PH, Aguilar C, Cornell J. A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. Ann Intern Med 2000 May 2;132(9):743-756. 11. Montgomery SA, Henry J, McDonald G, et al. Selective serotonin reuptake inhibitors: meta-analysis of discontinuation rates. Int Clin Psychopharmacol 1994 Spring;9(1):47-53. 12. Mulrow CD, Williams JW, Jr., Chiquette E, et al. Efficacy of newer medications for treating depression in primary care patients. Am J Med 2000 Jan;108(1):54-64. 13. Anderson IM. Meta-analytical studies on new antidepressants. Br Med Bull 2001;57:161-178. 14. Ustun TB, Ayuso-Mateos JL, Chatterji S, et al. Global burden of depressive disorders in the year 2000.[see comment]. Br J Psychiatry 2004 May;184:386-392. 15. Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry 2003 Dec;64(12):1465-1475. 16. Morgan SG, McMahon M, Mitton C, et al. Centralized drug review processes in Australia, Canada, New Zealand, and the United kingdom.[see comment]. Health Aff (Millwood) 2006 Mar-Apr;25(2):337-347. 17. Morden NE, Garrison LP, Jr., Morden NE, Garrison LP, Jr. Implications of Part D for mentally ill dual eligibles: a challenge for Medicare. Health Aff (Millwood) 2006 Mar-Apr;25(2):491-500. 18. Alonso J, Lepine JP. Overview of key data from the European Study of the Epidemiology of Mental Disorders (ESEMeD). J Clin Psychiatry 2007;68 Suppl 2:3-9. 19. Burt VK, Stein K. Epidemiology of depression throughout the female life cycle. J Clin Psychiatry 2002;63 Suppl 7:9-15. 20. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994 Jan;51(1):8-19. 21. American Psychiatric Association. Depressive disorders. In: American Psychiatric Association, ed. Diagnostic and Statistical Manual of Mental Disorder. Fourth ed. Washington ,DC: American Psychiatric Association; 2000: 369-381. 22. Gelenberg AJ, Hopkins HS. Assessing and treating depression in primary care medicine. Am J Med 2007 Feb;120(2):105-108. 23. Thase ME. Redefining antidepressant efficacy toward long-term recovery. J Clin Psychiatry 1999;60 Suppl 6:15-19. 24. Finley PR, Laird LK, Benefield WH. Mood Disorder Ι:Major Depressive Disorders. In: Koda-Kimble MA, Young LY, Kradjan WA, Guglielmo BJ, Alldredge BK, Corelli RL, eds. Applied therapeutics: the clinical use of drugs. 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2005: 79-71-37. 25. Kupfer DJ. Long-term treatment of depression. J Clin Psychiatry 1991 May;52 Suppl:28-34. 26. Stahl SM. Basic psychopharmacology of antidepressants, part 1: Antidepressants have seven distinct mechanisms of action. J Clin Psychiatry 1998;59 Suppl 4:5-14. 27. Mann JJ. The medical management of depression. N Engl J Med 2005 Oct 27;353(17):1819-1834. 28. Gumnick JF, Nemeroff CB. Problems with currently available antidepressants. J Clin Psychiatry 2000;61 Suppl 10:5-15. 29. Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 2000 Apr;58(1):19-36. 30. Anderson IM. SSRIS versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depress Anxiety 1998;7 Suppl 1:11-17. 31. Shelton RC. The dual-action hypothesis: does pharmacology matter? J Clin Psychiatry 2004;65 Suppl 17:5-10. 32. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62. 33. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979 Apr;134:382-389. 34. Guy W. ECDEU Assessment Manual for Psychopharmacology. 1976:218-222. 35. Greden JF. The burden of disease for treatment-resistant depression. J Clin Psychiatry 2001;62 Suppl 16:26-31. 36. Ferrier IN. Treatment of major depression: is improvement enough? J Clin Psychiatry 1999;60 Suppl 6:10-14. 37. Frank E, Prien RF, Jarrett RB, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 1991 Sep;48(9):851-855. 38. Thase ME, Rush AJ. Treatment-resistant depression. New York: Raven Press Ltd; 1995. 39. Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 1996 Jun;19(2):179-200. 40. Hirschfeld RM, Montgomery SA, Aguglia E, et al. Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. J Clin Psychiatry 2002 Sep;63(9):826-837. 41. Souery D, Papakostas GI, Trivedi MH. Treatment-resistant depression. J Clin Psychiatry 2006;67 Suppl 6:16-22. 42. Keller MB. Issues in treatment-resistant depression. J Clin Psychiatry 2005;66 Suppl 8:5-12. 43. Danileviciute V, Sveikata A. Present-day approach to pharmacological and clinical aspects of novel antidepressants. Medicina (Kaunas) 2002;38(12):1147-1156. 44. Rush AJ, Thase ME, Dube S. Research issues in the study of difficult-to-treat depression. Biol Psychiatry 2003 Apr 15;53(8):743-753. 45. Nelson JC. Managing treatment-resistant major depression. J Clin Psychiatry 2003;64 Suppl 1:5-12. 46. Rosenzweig-Lipson S, Beyer CE, Hughes ZA, et al. Differentiating antidepressants of the future: efficacy and safety. Pharmacol Ther 2007 Jan;113(1):134-153. 47. Fava M. Augmentation and combination strategies in treatment-resistant depression. J Clin Psychiatry 2001;62 Suppl 18:4-11. 48. Shelton RC. The use of antidepressants in novel combination therapies. J Clin Psychiatry 2003;64 Suppl 2:14-18. 49. Marangell LB. Switching antidepressants for treatment-resistant major depression. J Clin Psychiatry 2001;62 Suppl 18:12-17. 50. Ruhe HG, Huyser J, Swinkels JA, Schene AH. Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. J Clin Psychiatry 2006 Dec;67(12):1836-1855. 51. Etminan M, Wright JM, Carleton BC. Evidence-based pharmacotherapy: review of basic concepts and applications in clinical practice. Ann Pharmacother 1998 Nov;32(11):1193-1200. 52. Bero L, Rennie D. The Cochrane Collaboration. Preparing, maintaining, and disseminating systematic reviews of the effects of health care. JAMA 1995 Dec 27;274(24):1935-1938. 53. Robinson A. Research, practice and the Cochrane Collaboration. Cmaj 1995 Mar 15;152(6):883-889. 54. Horvath AR, Pewsner D. Systematic reviews in laboratory medicine: principles, processes and practical considerations. Clin Chim Acta 2004 Apr;342(1-2):23-39. 55. Sauerland S, Seiler CM. Role of systematic reviews and meta-analysis in evidence-based medicine. World J Surg 2005 May;29(5):582-587. 56. Green S. Systematic reviews and meta-analysis. Singapore Med J 2005 Jun;46(6):270-273; quiz 274. 57. Koretz RL. Methods of meta-analysis: an analysis. Curr Opin Clin Nutr Metab Care 2002 Sep;5(5):467-474. 58. Petticrew M. Systematic reviews from astronomy to zoology: myths and misconceptions. Bmj 2001 Jan 13;322(7278):98-101. 59. Sutton AJ, Cooper NJ, Jones DR, Lambert PC, Thompson JR, Abrams KR. Evidence-based sample size calculations based upon updated meta-analysis. Stat Med 2007 May 30;26(12):2479-2500. 60. Bardia A, Barton DL, Prokop LJ, Bauer BA, Moynihan TJ. Efficacy of complementary and alternative medicine therapies in relieving cancer pain: a systematic review. J Clin Oncol 2006 Dec 1;24(34):5457-5464. 61. Egger M, Smith GD, Phillips AN. Meta-analysis: principles and procedures. Bmj 1997 Dec 6;315(7121):1533-1537. 62. Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol 2000 Nov;53(11):1119-1129. 63. Kennedy SH, Andersen HF, Lam RW, Kennedy SH, Andersen HF, Lam RW. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis.[erratum appears in J Psychiatry Neurosci. 2006 Jul;31(4):228]. J Psychiatry Neurosci 2006 Mar;31(2):122-131. 64. Kasper S, Spadone C, Verpillat P, et al. Onset of action of escitalopram compared with other antidepressants: results of a pooled analysis. Int Clin Psychopharmacol 2006 Mar;21(2):105-110. 65. Eckert L, Lancon C, Eckert L, Lancon C. Duloxetine compared with fluoxetine and venlafaxine: use of meta-regression analysis for indirect comparisons. BMC Psychiatry 2006;6:30. 66. Vis PM, van Baardewijk M, Einarson TR, Vis PM, van Baardewijk M, Einarson TR. Duloxetine and venlafaxine-XR in the treatment of major depressive disorder: a meta-analysis of randomized clinical trials. Ann Pharmacother 2005 Nov;39(11):1798-1807. 67. Thase ME, Haight BR, Richard N, et al. Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatry 2005 Aug;66(8):974-981. 68. Llorca PM, Azorin JM, Despiegel N, et al. Efficacy of escitalopram in patients with severe depression: a pooled analysis. Int J Clin Pract 2005 Mar;59(3):268-275. 69. Hansen RA, Gartlehner G, Lohr KN, et al. Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Ann Intern Med 2005 Sep 20;143(6):415-426. 70. Einarson TR, Einarson TR. Evidence based review of escitalopram in treating major depressive disorder in primary care.[erratum appears in Int Clin Psychopharmacol. 2004 Nov;19(6):363]. Int Clin Psychopharmacol 2004 Sep;19(5):305-310. 71. Rudolph RL, Rudolph RL. Achieving remission from depression with venlafaxine and venlafaxine extended release: a literature review of comparative studies with selective serotonin reuptake inhibitors. Acta Psychiatr Scand Suppl 2002(415):24-30. 72. Thase ME, Entsuah AR, Rudolph RL, Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors.[see comment]. Br J Psychiatry 2001 Mar;178:234-241. 73. Bielski RJ, Ventura D, Chang CC. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry 2004 Sep;65(9):1190-1196. 74. Boulenger JP, Huusom AK, Florea I, et al. A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients. Curr Med Res Opin 2006 Jul;22(7):1331-1341. 75. Burke WJ, Gergel I, Bose A, Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 2002 Apr;63(4):331-336. 76. Chouinard G, Saxena B, Belanger MC, et al. A Canadian multicenter, double-blind study of paroxetine and fluoxetine in major depressive disorder. J Affect Disord 1999 Jul;54(1-2):39-48. 77. Colonna L, Andersen HF, Reines EH, Colonna L, Andersen HF, Reines EH. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder. Curr Med Res Opin 2005 Oct;21(10):1659-1668. 78. Detke MJ, Wiltse CG, Mallinckrodt CH, et al. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Neuropsychopharmacol 2004 Dec;14(6):457-470. 79. Fava M, Hoog SL, Judge RA, et al. Acute efficacy of fluoxetine versus sertraline and paroxetine in major depressive disorder including effects of baseline insomnia. J Clin Psychopharmacol 2002 Apr;22(2):137-147. 80. Feighner JP, Gardner EA, Johnston JA, et al. Double-blind comparison of bupropion and fluoxetine in depressed outpatients. J Clin Psychiatry 1991 Aug;52(8):329-335. 81. Goldstein DJ, Mallinckrodt C, Lu Y, et al. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry 2002 Mar;63(3):225-231. 82. Kasper S, de Swart H, Friis Andersen H, Kasper S, de Swart H, Friis Andersen H. Escitalopram in the treatment of depressed elderly patients. Am J Geriatr Psychiatry 2005 Oct;13(10):884-891. 83. Kavoussi RJ, Segraves RT, Hughes AR, et al. Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients. J Clin Psychiatry 1997 Dec;58(12):532-537. 84. Leinonen E, Skarstein J, Behnke K, et al. Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group. Int Clin Psychopharmacol 1999 Nov;14(6):329-337. 85. Mehtonen OP, Sogaard J, Roponen P, et al. Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder. Venlafaxine 631 Study Group.[see comment]. J Clin Psychiatry 2000 Feb;61(2):95-100. 86. Montgomery SA, Huusom AK, Bothmer J, Montgomery SA, Huusom AKT, Bothmer J. A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology 2004;50(1):57-64. 87. Moore N, Verdoux H, Fantino B, Moore N, Verdoux H, Fantino B. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol 2005 May;20(3):131-137. 88. Newhouse PA, Krishnan KR, Doraiswamy PM, et al. A double-blind comparison of sertraline and fluoxetine in depressed elderly outpatients. J Clin Psychiatry 2000 Aug;61(8):559-568. 89. Rapaport M, Coccaro E, Sheline Y, et al. A comparison of fluvoxamine and fluoxetine in the treatment of major depression. J Clin Psychopharmacol 1996 Oct;16(5):373-378. 90. Rudolph RL, Feiger AD, Rudolph RL, Feiger AD. A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression.[see comment]. J Affect Disord 1999 Dec;56(2-3):171-181. 91. Sechter D, Troy S, Paternetti S, et al. A double-blind comparison of sertraline and fluoxetine in the treatment of major depressive episode in outpatients. Eur Psychiatry 1999 Mar;14(1):41-48. 92. Silverstone PH, Ravindran A, Silverstone PH, Ravindran A. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group.[see comment]. J Clin Psychiatry 1999 Jan;60(1):22-28. 93. Weihs KL, Settle EC, Jr., Batey SR, et al. Bupropion sustained release versus paroxetine for the treatment of depression in the elderly.[see comment]. J Clin Psychiatry 2000 Mar;61(3):196-202. 94. Ekselius L, von Knorring L, Eberhard G, Ekselius L, von Knorring L, Eberhard G. A double-blind multicenter trial comparing sertraline and citalopram in patients with major depression treated in general practice. Int Clin Psychopharmacol 1997 Nov;12(6):323-331. 95. Kroenke K, West SL, Swindle R, et al. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial.[see comment]. Jama 2001 Dec 19;286(23):2947-2955. 96. Patris M, Bouchard JM, Bougerol T, et al. Citalopram versus fluoxetine: a double-blind, controlled, multicentre, phase III trial in patients with unipolar major depression treated in general practice. Int Clin Psychopharmacol 1996 Jun;11(2):129-136. 97. Lepola UM, Loft H, Reines EH, Lepola UM, Loft H, Reines EH. Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2003 Jul;18(4):211-217. 98. Dalery J, Honig A, Dalery J, Honig A. Fluvoxamine versus fluoxetine in major depressive episode: a double-blind randomised comparison. Hum 2003 Jul;18(5):379-384. 99. Cassano GB, Puca F, Scapicchio PL, et al. Paroxetine and fluoxetine effects on mood and cognitive functions in depressed nondemented elderly patients. J Clin Psychiatry 2002 May;63(5):396-402. 100. De Wilde J, Spiers R, Mertens C, et al. A double-blind, comparative, multicentre study comparing paroxetine with fluoxetine in depressed patients. Acta Psychiatr Scand 1993 Feb;87(2):141-145. 101. Schone W, Ludwig M, Schone W, Ludwig M. A double-blind study of paroxetine compared with fluoxetine in geriatric patients with major depression. J Clin Psychopharmacol 1993 Dec;13(6 Suppl 2):34S-39S. 102. Fava M, Amsterdam JD, Deltito JA, et al. A double-blind study of paroxetine, fluoxetine, and placebo in outpatients with major depression. Ann Clin Psychiatry 1998 Dec;10(4):145-150. 103. Bennie EH, Mullin JM, Martindale JJ, Bennie EH, Mullin JM, Martindale JJ. A double-blind multicenter trial comparing sertraline and fluoxetine in outpatients with major depression. J Clin Psychiatry 1995 Jun;56(6):229-237. 104. Boyer P, Danion JM, Bisserbe JC, et al. Clinical and economic comparison of sertraline and fluoxetine in the treatment of depression. A 6-month double-blind study in a primary-care setting in France. Pharmacoeconomics 1998 Jan;13(1 Pt 2):157-169. 105. Aberg-Wistedt A, Agren H, Ekselius L, et al. Sertraline versus paroxetine in major depression: clinical outcome after six months of continuous therapy. J Clin Psychopharmacol 2000 Dec;20(6):645-652. 106. Nemeroff C, Ninan P, Ballenger J, Lydiard R, Feighner J, Patterson W. Double-blind multicenter comparison of fluvoxamine versus sertralinein the treatment of depressed outpatients. Depression 1995;3:163-169. 107. Franchini L, Gasperini M, Perez J, et al. A double-blind study of long-term treatment with sertraline or fluvoxamine for prevention of highly recurrent unipolar depression. J Clin Psychiatry 1997 Mar;58(3):104-107. 108. Gagiano C. A double blind comparison of paroxetine and fluoxetine in patients with major depression. British Journal of Clinical Research 1993;4:145-152. 109. Kiev A, Feiger A, Kiev A, Feiger A. A double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients. J Clin Psychiatry 1997 Apr;58(4):146-152. 110. Coleman CC, King BR, Bolden-Watson C, et al. A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine. Clin Ther 2001 Jul;23(7):1040-1058. 111. Hong CJ, Hu WH, Chen CC, et al. A double-blind, randomized, group-comparative study of the tolerability and efficacy of 6 weeks' treatment with mirtazapine or fluoxetine in depressed Chinese patients. J Clin Psychiatry 2003 Aug;64(8):921-926. 112. Alves C, Cachola I, Brandao J. Efficacy and tolerability of venlafaxine and fluoxetine in outpatients with major depression. Primary Care Psychiatry 1999;5:57-63. 113. Tylee A, Beaumont G, Bowden M, Reynolds A. A double-blind,randomized,12-week comparison study of the safety and efficacy of venlafaxine and fluoxetine in moderate to severe depression in general practice. Primary Care Psychiatry 1997;3:51-58. 114. Dierick M, Ravizza L, Realini R, et al. A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Prog Neuropsychopharmacol Biol Psychiatry 1996 Jan;20(1):57-71. 115. De Nayer A, Geerts S, Ruelens L, et al. Venlafaxine compared with fluoxetine in outpatients with depression and concomitant anxiety. Int J Neuropsychopharmcol 2002 Jun;5(2):115-120. 116. Schatzberg AF, Kremer C, Rodrigues HE, et al. Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients. Am J Geriatr Psychiatry 2002 Sep-Oct;10(5):541-550. 117. Benkert O, Szegedi A, Kohnen R, Benkert O, Szegedi A, Kohnen R. Mirtazapine compared with paroxetine in major depression. J Clin Psychiatry 2000 Sep;61(9):656-663. 118. Ballus C, Quiros G, De Flores T, et al. The efficacy and tolerability of venlafaxine and paroxetine in outpatients with depressive disorder or dysthymia. Int Clin Psychopharmacol 2000 Jan;15(1):43-48. 119. Coleman CC, Cunningham LA, Foster VJ, et al. Sexual dysfunction associated with the treatment of depression: a placebo-controlled comparison of bupropion sustained release and sertraline treatment. Ann Clin Psychiatry 1999 Dec;11(4):205-215. 120. Croft H, Settle E, Jr., Houser T, et al. A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline. Clin Ther 1999 Apr;21(4):643-658. 121. Behnke K, Sogaard J, Martin S, et al. Mirtazapine orally disintegrating tablet versus sertraline: a prospective onset of action study.[erratum appears in J Clin Psychopharmacol. 2003 Dec;23(6):682]. J Clin Psychopharmacol 2003 Aug;23(4):358-364. 122. Bielski RJ, Ventura D, Chang CC, Bielski RJ, Ventura D, Chang C-C. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry 2004 Sep;65(9):1190-1196. 123. Costa e Silva J, Costa e Silva J. Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression.[see comment]. J Clin Psychiatry 1998 Jul;59(7):352-357. 124. Doraiswamy PM, Khan ZM, Donahue RM, et al. Quality of life in geriatric depression: a comparison of remitters, partial responders, and nonresponders. Am J Geriatr Psychiatry 2001;9(4):423-428. 125. McPartlin G, Reynolds A, Anderson C, Casoy J. A comparison of oncedaily venlafaxine XR and paroxetine in depressed outpatients treated in general practice. Primary Care Psychiatry 1998;4:127-132. 126. Owens MJ, Knight DL, Nemeroff CB. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 2001 Sep 1;50(5):345-350. 127. Llorca PM, Azorin JM, Despiegel N, Verpillat P. Efficacy of escitalopram in patients with severe depression: a pooled analysis. Int J Clin Pract 2005 Mar;59(3):268-275. 128. Lepola U, Wade A, Andersen HF. Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder. Int Clin Psychopharmacol 2004 May;19(3):149-155. 129. Gorman JM, Korotzer A, Su G. Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials. CNS Spectr 2002 Apr;7(4 Suppl 1):40-44. 130. Llorca PM, Fernandez JL. Escitalopram in the treatment of major depressive disorder: clinical efficacy, tolerability and cost-effectiveness vs. venlafaxine extended-release formulation. Int J Clin Pract 2007 Apr;61(4):702-710. 131. Murdoch D, Keam SJ. Escitalopram: a review of its use in the management of major depressive disorder. Drugs 2005;65(16):2379-2404. 132. Sanchez C, Bogeso KP, Ebert B, Reines EH, Braestrup C. Escitalopram versus citalopram: the surprising role of the R-enantiomer. Psychopharmacology (Berl) 2004 Jul;174(2):163-176. 133. 程馨. 健保制度對原開發藥廠的影響. 公勞健保制度對藥事經濟發展的影響研討會之支付制度對產業及執業藥師的影響. 台北榮民總醫院: 中華景康藥學基金會; 2006. 134. 朱茂男. 公勞保沿革及支付制度對產業的影響. 公勞健保制度對藥事經濟發展的影響研討會之支付制度對產業及執業藥師的影響. 台北榮民總醫院: 中華景康藥學基金會; 2006. 135. Smith W, Sherrill A, Smith W, Sherrill A. A pharmacoeconomic study of the management of major depression: patients in a TennCare HMO.[erratum appears in Med Interface 1996 Oct;9(10):86]. Med Interface 1996 Jul;9(7):88-92. 136. 曾千芳. 健保藥價基準修訂原則說明. 公勞健保制度對藥事經濟發展的影響研討會之支付制度對產業及執業藥師的影響. 台北榮民總醫院: 中華景康藥學基金會; 2006. 137. 黃肇明. 全民健保藥品支付與藥價基準. 藥事行政及法規上課講義: 台大藥學系; 2006. 138. Brekke KR, Konigbauer I, Straume OR. Reference pricing of pharmaceuticals. J Health Econ 2007 May;26(3):613-642. 139. Lopez-Casasnovas G, Puig-Junoy J. Review of the literature on reference pricing. Health Policy 2000 Nov 17;54(2):87-123. 140. Ioannides-Demos LL, Ibrahim JE, McNeil JJ. Reference-based pricing schemes: effect on pharmaceutical expenditure, resource utilisation and health outcomes. Pharmacoeconomics 2002;20(9):577-591. 141. Aaserud M, Dahlgren AT, Kosters JP, Oxman AD, Ramsay C, Sturm H. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies. Cochrane Database Syst Rev 2006(2):CD005979. 142. Mullens A. Reference-based pricing: will other provinces follow the BC lead? Cmaj 1998 Jan 27;158(2):239-241. 143. Bourgault C, Elstein E, Le Lorier J, Suissa S. Reference-based pricing of prescription drugs: exploring the equivalence of angiotensin-converting-enzyme inhibitors. Cmaj 1999 Aug 10;161(3):255-260. 144. Danzon PM, Ketcham JD. Reference pricing of pharmaceuticals for Medicare: evidence from Germany, The Netherlands, and New Zealand. Front Health Policy Res 2004;7:1-54. 145. Thomas M. The change of cost: reference-based pricing and the statins. Can J Cardiol 1999 May;15(5):535-538. 146. Thomas M, Mann J. Increased thrombotic vascular events after change of statin. Lancet 1998 Dec 5;352(9143):1830-1831. 147. 許光宏, 盧瑞芬, 潘美真. 全民健康保險藥品差額負擔可行性之研究. In: 長庚大學醫務管理學系, ed.: 行政院衛生署八十七年度委託研究計畫; 1998. 148. Weiden PJ. Discontinuing and switching antipsychotic medications: understanding the CATIE schizophrenia trial. J Clin Psychiatry 2007;68 Suppl 1:12-19. 149. 董倫銓. 全民健保實施總額預算對我國藥事政策影響之研究 銘傳大學; 2002. 150. Eaddy MT, Druss BG, Sarnes MW, Regan TS, Frankum LE. Relationship of total health care charges to selective serotonin reuptake inhibitor utilization patterns including the length of antidepressant therapy--results from a managed care administrative claims database. J Manag Care Pharm 2005 Mar;11(2):145-150. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/29190 | - |
dc.description.abstract | 研究背景:憂鬱症是一種高盛行率且失能程度嚴重的慢性疾病,藥物治療為憂鬱症之主要治療方式。第二代抗憂鬱劑特點為副作用小且療效和三環類抗鬱劑(tricyclic antidepressants, TCA)和單胺氧化酶抑制劑(monoamine oxidase inhibitor, MAOI)相當,故迅速成為臨床治療的第一選擇。健保局曾在2003年3月1日,單獨將第二代抗憂鬱劑fluoxetine 20 mg/tab之原廠藥(Prozac®)由每錠43.8元調降為18.7元,但其他第二代抗憂鬱劑僅微幅調降,因此造成抗憂鬱劑市場大變動。此種單一品項藥品大幅降價的措施,是否能有效達到健保控制藥費的目的?且對SSRI類及其他相關抗憂鬱劑的臨床使用的影響,一直受到醫藥界的關心與質疑。
研究目的:第一部份由醫學文獻資料庫搜尋第二代抗憂鬱劑療效相關文獻並比較第二代抗憂鬱劑各個藥物間及療效。第二部份針對使用fluoxetine病人進行研究,分析單一品項藥價大幅調降後對於醫師處方行為和病人權益的影響。 研究方法:第一部份利用系統性文獻回顧(systematic review)方法,分析比較第二代抗憂鬱劑藥物間的臨床療效。第二部份則利用向中央健康保險局申請的特殊主題健保資料庫檔「處方fluoxetine病患歸人檔(PMCDF)」為研究材料。由PMCDF資料庫中取得2003年1、2月連續兩個月處方Prozac®或fluoxetine學名藥大於7天,並且無處方其他第二代抗憂鬱劑的病人資料。分析在3月1日大幅調降Prozac®藥價之六個月內,Prozac®組或fluoxetine學名藥組病人的換藥情形,計算換藥率、續用率,進而分別分析換藥病人與續用病人的就醫次數、醫療資源耗用情況,並進行比較。 研究結果:由文獻搜尋找出Hansen RA et al(Ann Intern Med. 2005;143: 415-26.)為重鬱症綜合分析之代表性著作,並依據該篇的納入、排除條件,由所收集的文獻中,增加了5篇新的藥物和藥物直接作比較的研究,連同原收錄之46篇第二代抗憂鬱劑藥物和藥物直接作比較的文獻,共51篇文獻。综合分析結果顯示,fluoxetine vs.paroxetine (relative benefit(RB)= 1.05 (95% CI = 0.92 to 1.20)),兩組的最後反應率並沒有顯著的不同。Citalopram vs. escitalopram (RB= 1.06 (95% CI = 0.90 to 1.25)),也並沒有顯著的不同。Sertraline療效優於fluoxetine (RB= 1.10 (95% CI = 1.01to 1.20))。Venlafaxine療效優於fluoxetine (RB= 1.10 (95% CI = 1.01to 1.20))。 由PMCDF資料庫擷取出病人資料,Prozac®組5025位,fluoxetine學名藥組8739位,兩組的女性比例較高(56.75%、57.57%),平均年齡為47.0歲、48.8歲。兩組病人之換藥有90%以上皆為單一藥品品項的取代,Prozac®組換藥病人,以其他SSRI類藥物(50.86%)為主,且集中在區域醫院和醫學中心;fluoxetine學名藥組換藥病人,則以TCA+TeA類藥物(50.92%)為主,且集中在基層院所。Prozac®換藥組病人相較於同組續用病人,有較高之平均就醫次數(門診、精神科門診、急診、住院、精神科住院)。Fluoxetine學名藥組換藥病人相較於同組續用病人,在平均就醫次數,兩組無顯著差別。Prozac®組換藥病人相較於同組續用病人,有較高之醫療資源耗用。但fluoxetine學名藥組病人,卻呈現相反狀況;續用組病人相較於同組換藥病人,在門診、精神科門診有較高之醫療資源耗用,兩組無顯著差別。 結論:由第一部份的研究結果顯示,SSRI類藥物之間對於重鬱症的療效無顯著的差別。SSRI類的藥物和其他類藥物(SNRI, NaSSA, NDRI)的比較對於重鬱症的療效也無顯著差別。由第二部份的研究結果顯示,此種單一藥品藥價大幅調降措施,在初期(前三個月)有高於憂鬱症病人在常態下之換藥率。而且,所觀察到的換藥行為,有部分醫師係改為開立有較高藥價差利潤之高健保支付價之其他SSRI類藥物,對健保醫療資源的使用及分配,整體而言並非有益。此外,不同醫療機構層級別,有不同的健保藥品支付制度及進藥原則,也可能影響到醫師的處方行為,在基層院所有較多醫師可能因選擇使用簡表申請,而改採更低藥費之TCA+TeA類藥品。由病人及家屬的角度來看,單一藥品藥價大幅調降措施所可能導致的病人換藥,而有較多的就醫次數,都會產生一些有形、無形的負擔,進而影響到病人的權益。 | zh_TW |
dc.description.abstract | Background:Depression is a chronic mental disorder with high social burden due to its high prevalence rate and significant disability. Currently, drug therapy is the major strategy toward the depression treatment. Among those antidepressants, the second generation antidepressants quickly became the first drug choice in clinical therapy since they have less side effect profile and have similar efficacy when compared to tricyclic antidepressants (TCA) and monoamine oxidase inhibitor (MAOI). The reimbursement price of the 20 mg/tab branded fluoxetine (Prozac®) was reduced from NTD 43.8 to NTD 18.7 by the Bureau of National Health Insurance (BNHI) in March 1, 2003, but not to the other second generation antidepressants. It led to the redistribution of antidepressants market in Taiwan. Can this drug price reduction in deed achieve the goal to reduce the health insurance fee? Will this policy affect the usage of selective serotonin reuptake inhibitors (SSRI)?
Objective:Part I: To collect the papers related to the efficacy of second generation antidepressants and to compare the efficacy of them. Part II: Take fluoxetine as an example to analyze the impacts of dramatic price reduction in single SSRI antidepressant upon the doctor prescribing behaviors and patients benefits. Methods:Part I: The clinical efficacy of second generation antidepressants was analyzed through a systematic review of literature searched from Medline. Part II: The Patients Medical Claim Dataset with Fluoxetine (PMCDF) in Taiwan provided by BNHI was used for data analysis. Patients prescribed with Prozac® or generic fluoxetine more than or equal to 7 days in both January and February of 2003 with no prescription of any other antidepressants at the same time were retrieved. The changes of antidepressant prescriptions were analyzed after the implementation of fluoxetine price reduction policy on March,1 2003. Drug change ratio and the continuous use ratio for patients in Prozac® group and in generic fluoxetine group were calculated. In both groups, patients under changed prescription or continuous use were further sub-grouped into 2 antidepressant utilization cohorts: (1) continuous use and (2) drug change. The total number of medical visit, medical resource consumptions of those patients were then compared between the two antidepressant utilization cohorts for Prozac® patient group and generic fluoxetine patient group. Results:Part I: After literature search, the meta analysis for major depressive disorder (MDD), including 46 head to head clinical trials as indicated in the paper by Hansen RA et al. and 5 newly found head to head trials, were carried out. The rate of being a responder at study end did not differ significantly between fluoxetine and paroxetine (relative benefit,1.09 [95% CI, 0.97 to 1.21]). The efficacy of citalopram and escitalopram is similar. (relative benefit,1.06 [95% CI, 0.9 to 1.25]). A modest additional treatment effect (relative benefit, 1.10 [95% CI, 1.01 to 1.22]) for sertraline compared with fluoxetine; and modest additional treatment effect (relative benefit, 1.12 [95% CI, 1.02 to 1.23]) for venlafaxine compared with fluoxetine, were recognized. Part II: A total of 5025 patients and 8739 patients were included for Prozac® group and generic fluoxetine group, respectively. There were more woman in both two groups(56.75% and 57.57%) in both groups. The mean age of these patients in two groups was 47.0 year old and 48.8 year old. In drug change cohorts of both groups, more than 90% patients’ fluoxetine prescriptions were replaced by one other drug. The drug for replacement were mainly the SSRIs (50.86%) for Prozac® group and TCA+TeA (50.92%) for generic fluoxetine group. The prescription change patterns are different for both groups and depend on the type of medical institutions. In Prozac® group, the mean number of total medical visit in drug change cohorts was significantly higher than that in continuous use cohorts (general department, psychiatric department, emergency department, hospital admissions and psychiatric admissions). In generic fluoxetine group, there were no significant difference between the drug change cohorts and continuous use cohorts in terms of medical visits. In Prozac® group, the mean medical resource consumptions in drug change cohorts were significantly higher than those in continuous use cohorts. However, in generic fluoxetine group, the mean medical resource consumptions in drug change cohorts were significantly higher than those in continuous use cohorts with no significant difference. Conclusions:Part I: In MDD, the clinical efficacy in SSRIs is similar and the clinical efficacy between SNRIs SNRI, NaSSA, NDRI and SSRIs is similar. Part II: The policy of dramatic drug price reduction for single agent had significantly affect the prescription switched for the first three months after the policy implemented. There was a high percentage of the antidepression prescriptions switching to the other SSRIs with higher drug price profit. This is not necessarily beneficial for the use and distribution of BNHIs’ medical resources. Besides, different type of medical institution, different drug payment system and different drug inclusion principles may also influence doctors’ prescribing behaviors. For instance, the fixed-drug daily payment may lead doctors in clinics to use drugs with lower prices such as TCA with TeA. For patients and their family, they may not be informed with the change of antidepressant prescription, even worse that, such change may result in more medical visits and hence have impact on patients’ benefits. | en |
dc.description.provenance | Made available in DSpace on 2021-06-13T01:02:38Z (GMT). No. of bitstreams: 1 ntu-96-R94451003-1.pdf: 775546 bytes, checksum: 294afe6c53656538b348d1da6c0e6005 (MD5) Previous issue date: 2007 | en |
dc.description.tableofcontents | 口試委員會審定書 i
誌謝 ii 中文摘要 iii Abstract v 目錄 viii 圖目錄 x 表目錄 xiii 縮寫或簡稱對照表 xix 中英文名詞對照表 xx 第一章 前言 1 第二章 研究目的 3 第三章 第二代抗憂鬱劑類藥物療效之比較研究 4 第一節 文獻回顧 4 第二節 研究方法 13 第三節 研究結果 17 第四節 討論 38 第四章 藥價政策對醫師處方行為和病人權益影響之研究 41 第一節 文獻探討 41 第二節 研究方法 49 第三節 研究結果 62 第四節 討論 93 第五章 結論與建議 104 參考文獻 105 附錄 116 | |
dc.language.iso | zh-TW | |
dc.title | 藥價政策對於處方行為及病人權益影響之研究—
以抗憂鬱劑為例 | zh_TW |
dc.title | The impact of drug price policy on prescribing behaviors and patients right--Analysis of antidepressants | en |
dc.type | Thesis | |
dc.date.schoolyear | 95-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 高雅慧,張景瑞,高淑芬 | |
dc.subject.keyword | 藥價政策,處方行為,健保資料庫,抗憂鬱劑,選擇性血清促進素再吸收抑制劑, | zh_TW |
dc.subject.keyword | Drug price policy,prescribing behaviors,national health insurance database,antidepressants,selective serotonin reuptake inhibitor, | en |
dc.relation.page | 124 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2007-07-25 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 臨床藥學研究所 | zh_TW |
顯示於系所單位: | 臨床藥學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-96-1.pdf 目前未授權公開取用 | 757.37 kB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。